Goals and objectives: The overarching theme of the Center is the development of novel therapeutics targeting sustained CNS inflammation for HIV-associated neurocognitive disorders (HAND). We have identified this as a high priority on the basis of our institutional strengths, our studies of neuropathogenesis, and the continuing importance in clinical care of these disorders. Organization of the Administrative Core The Administrative Core consists ofthe Executive Committee, an Operations Office, and an External Advisory Committee (EAC) to provide 'high-altitude'guidance and oversight. The Executive Committee consists ofthe Director, Co-Directors, and an administrator for the Center. Policies and procedures to be used by the Center are included in the Research Plan, and as Appendix material. Objectives of the Administrative Core To facilitate the development of novel therapeutics for HIV-associated neurocognitive disorders by facilitating collaborative research in HIV-related neuroscience among the widest possible range ofthe JHU academic community;increasing resources for HIV-related neuroscience;enhancing the productivity of HIV-related neuroscience research locally, nationally and internationally;encouraging high-risk, innovative 'developmental'research;encouraging and provide resources for new investigators;and providing educational resources for non-neurologists involved in HIV care for HIV-related neurological complications, and to facilitate participation in research. The core will also be responsible for the development of a web based, interactive "virtual cohort" to assemble individuals in the USA with HAND.

Public Health Relevance

HIV/AIDS is a major threat to global health and urban America, and HIV-associated-neurocognitive dysfunction remains prevalent even in HAART-treated people. Our research suggests that one ofthe drivers for this is sustained inflammation within the brain. Our Center has helped to coordinate and catalyze scientific and clinical resources at JHU to generate novel approaches to therapy.

National Institute of Health (NIH)
National Institute of Mental Health (NIMH)
Center Core Grants (P30)
Project #
Application #
Study Section
Special Emphasis Panel (ZMH1-ERB-F)
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Johns Hopkins University
United States
Zip Code
Sacktor, Ned; Nakasujja, Noeline; Redd, Andrew D et al. (2014) HIV subtype is not associated with dementia among individuals with moderate and advanced immunosuppression in Kampala, Uganda. Metab Brain Dis 29:261-8
Meulendyke, Kelly A; Croteau, Joshua D; Zink, M Christine (2014) HIV life cycle, innate immunity and autophagy in the central nervous system. Curr Opin HIV AIDS 9:565-71
Sacktor, Ned; Miyahara, Sachiko; Evans, Scott et al. (2014) Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment. J Neurovirol 20:620-6
Gamaldo, Charlene E; Gamaldo, Alyssa; McArthur, Justin C et al. (2014) Reply: To PMID 23722610. J Acquir Immune Defic Syndr 65:e124-5
Hulgan, Todd; Levinson, Rebecca T; Gerschenson, Mariana et al. (2014) Epidermal nerve fiber density, oxidative stress, and mitochondrial haplogroups in HIV-infected Thais initiating therapy. AIDS 28:1625-33
Yu, Ian W; Espinoza, Diego A; McAlexander, Melissa A et al. (2014) OpenArray profiling reveals no differential modulation of miRNA by positive and negative CD4+ T cell immunoselection. Exp Hematol 42:11-3
Figuera-Losada, Mariana; Rojas, Camilo; Slusher, Barbara S (2014) Inhibition of microglia activation as a phenotypic assay in early drug discovery. J Biomol Screen 19:17-31
Bora, Adriana; Ubaida Mohien, Ceereena; Chaerkady, Raghothama et al. (2014) Identification of putative biomarkers for HIV-associated neurocognitive impairment in the CSF of HIV-infected patients under cART therapy determined by mass spectrometry. J Neurovirol 20:457-65
Bae, Mihyun; Patel, Neha; Xu, Haoxing et al. (2014) Activation of TRPML1 clears intraneuronal A? in preclinical models of HIV infection. J Neurosci 34:11485-503
Meulendyke, Kelly A; Queen, Suzanne E; Engle, Elizabeth L et al. (2014) Combination fluconazole/paroxetine treatment is neuroprotective despite ongoing neuroinflammation and viral replication in an SIV model of HIV neurological disease. J Neurovirol 20:591-602

Showing the most recent 10 out of 60 publications